Announcement PDF Racura Oncology Ltd • ABN 61 149 318 749 • L36 1 Macquarie Place Sydney NSW 2000 Australia T. +61 2 8051 3043 • E. info@racuraoncology.com • www.racuraoncology.com ASX Announcement Change of Company Name 9 December 2025 – Racura Oncology Ltd (“Racura”, ASX:RAC) is pleased to announce following shareholder approval at the Company’s 2025 Annual General Meeting held on Monday, 24 November 2025, the name of the company will change from Race Oncology Limited to Racura Oncology Ltd. This change has been recorded by the Australian Securities and Investments Commission (ASIC) with effect from 5 December 2025. The ASX will implement the Company’s change of name from the commencement of trading on Wednesday, 10 December 2025. There is no change to the Company’s ASX listing code “RAC”. -ENDS- About Racura Oncology (ASX: RAC) Racura Oncology (ASX: RAC) is a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Racura’s lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1. Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase 3 clinical programs in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients. Racura Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle. Racura is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com. If you have any questions on this announcement, or any past Racura Oncology announcements please visit our Interactive Announcements page. Racura encourages all investors to go paperless by registering their details with the Company’s share registry, Automic Registry Services, at www.automicgroup.com.au. Release authorised by: Daniel Tillett, CEO info@racuraoncology.com Media contact: Cherie Hartley +61 418 737 020 cherie.hartley@irdepartment.com.au